SCD and Alzheimer disease: To assess if central SCD inhibition improves peripheral metabolic features of AD, we employed the same protocol as previously25, infusing the Abcam SCDi ICV for 1-month in memory-impaired 9-month-old 3xTg-AD mice and WT strain controls (Fig. 3a).